Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 What does ALLHAT tell us about dyslipidemia from the hypertension specialist perspective?

× No keyword cloud information.

7 in total

1. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal: Lancet Date: 2003-04-05 Impact factor: 79.321

2. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:
Journal: JAMA Date: 2002-12-18 Impact factor: 56.272

3. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Authors:
Journal: JAMA Date: 2002-12-18 Impact factor: 56.272

Review 4. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants.

Authors: Kausik K Ray; Sreenivasa Rao Kondapally Seshasai; Sebhat Erqou; Peter Sever; J Wouter Jukema; Ian Ford; Naveed Sattar
Journal: Arch Intern Med Date: 2010-06-28

5. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors: Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal: N Engl J Med Date: 2008-11-09 Impact factor: 91.245

Review 6. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors: Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal: Circulation Date: 2004-07-13 Impact factor: 29.690

7. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Authors: Karen L Margolis; Barry R Davis; Charles Baimbridge; Jerry O Ciocon; Aloysius B Cuyjet; Richard A Dart; Paula T Einhorn; Charles E Ford; David Gordon; Thomas J Hartney; L Julian Haywood; Jordan Holtzman; David E Mathis; Suzanne Oparil; Jeffrey L Probstfield; Lara M Simpson; John D Stokes; Thomas B Wiegmann; Jeff D Williamson
Journal: J Clin Hypertens (Greenwich) Date: 2013-06-10 Impact factor: 3.738

7 in total